Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
about
The β-glucan from Lentinus edodes suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers.Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen.Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine
P2860
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
@en
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
@nl
type
label
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
@en
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
@nl
prefLabel
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
@en
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy
@en
P2093
Rajesh Agarwal
Ruiwen Zhang
Sukesh Voruganti
P2860
P304
32566-32578
P356
10.18632/ONCOTARGET.8873
P407
P577
2016-04-20T00:00:00Z